World's Best Scientists 2026 revealed!
Francisco Cervantes

Francisco Cervantes

Award Badge
Medicine
Spain
2023

D-Index & Metrics

Medicine

D-Index
99
Citations
59691
World Ranking
8412
National Ranking
120

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Francisco Cervantes is affiliated with the University of Barcelona in Spain and has contributed extensively to the field of medicine, particularly focusing on hematology and related subfields. Their research portfolio includes significant work in genetics, molecular biology, rheumatology, and hepatology.

Cervantes' research interests primarily cover clinical and molecular aspects of blood disorders. Key topics explored in their work include:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Kruppel-like factors research
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Hemoglobinopathies and Related Disorders

The scientist has published research in a variety of academic journals, demonstrating a broad publication presence. Frequent venues include:

  • Leukemia
  • Journal of Hepatology
  • Clinical Lymphoma Myeloma & Leukemia
  • Annals of Hematology
  • Blood

Among recent published papers, several notable works feature Cervantes as an author. These include:

  • "Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study", 2021, Leukemia
  • "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia", 2020, Leukemia (authored primarily by Andreas Hochhaus with Cervantes contributions in the field)
  • "The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia", 2020, Leukemia (authored primarily by Markus Pfirrmann)
  • "Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis", 2022, Leukemia (authored primarily by Ruben A. Mesa)
  • "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis", 2020, Journal of Hepatology (authored primarily by Marta Magaz)

Cervantes has co-authored publications with several frequent collaborators, including:

  • Alberto Álvarez-Larrán
  • Alessandro M. Vannucchi
  • Ruben A. Mesa
  • Timothy Devos
  • Jean-Jacques Kiladjian

With a cumulative body of 73 publications in medicine, Cervantes' work illustrates a specialized focus on hematology with 22 publications in this subfield and a substantive contribution to genetics with 30 related publications.

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

    Claire Harrison;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali;Heinz Gisslinger

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

    Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti

  • Prognostic discrimination in "good-risk" chronic granulocytic leukemia

    JE Sokal;EB Cox;M Baccarani;S Tura

  • Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

    Thomas Ernst;Andrew J Chase;Andrew J Chase;Joannah Score;Joannah Score;Claire E Hidalgo-Curtis;Claire E Hidalgo-Curtis

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    Naseema Gangat;Domenica Caramazza;Rakhee Vaidya;Geeta George

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

    Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka

  • Mutations and prognosis in primary myelofibrosis

    Alessandro Maria Vannucchi;Tl Lasho;Paola Guglielmelli;Flavia Biamonte

  • A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    Francesco Passamonti;Francisco Cervantes;Alessandro Maria Vannucchi;Enrica Morra

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

    C.N Harrison;A.M. Vannucchi;J.-J. Kiladjian;H.K. Al-Ali

Frequent Co-Authors

Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Francesco Passamonti
Francesco Passamonti University of Milan
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust
Emili Montserrat
Emili Montserrat University of Barcelona
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Giovanni Barosi
Giovanni Barosi University of Pavia
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Dolors Colomer
Dolors Colomer University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Choosing to study medicine in the USA opens doors to a variety of related healthcare careers and academic pathways. Many students pursue online degrees to build their skills or advance professionally while maintaining flexibility.

For those interested in food science and patient care, an online BS in nutrition can be a strong starting point, offering foundational knowledge in dietetics and wellness.

Aspiring healthcare administrators can benefit from reputable online MHA programs. These master’s degrees, especially those accredited by CAHME, provide essential leadership and management skills for navigating the complex healthcare system.

For registered nurses seeking to advance their qualifications, online RN to BSN programs no clinicals allow for a convenient transition without requiring additional in-person clinical hours, making upskilling more accessible.

Finally, for those aiming for the highest level of nursing practice, the shortest online DNP program options help experienced nurses achieve their doctorate efficiently, opening the door to leadership, research, and education roles.

Best Scientists Citing Francisco Cervantes

Trending Scientists